Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Methods The original version of this document was developed in consultation with the
International Forum for Acute Care Trialists (InFACT), International Severe Acute Respiratory …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus
disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time …

Purpose This executive summary of a national living guideline aims to provide rapid
evidence based recommendations on the role of drug interventions in the treatment of …

Introduction Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …

ABSTRACT The COVID-19 Treatment Guidelines were developed to provide clinicians with
guidance on caring for patients with COVID-19. Because clinical information about the …

Background Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute
respiratory syndrome-coronavirus-2. Consensus suggestions can standardise care, thereby …

Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine Drug treatment
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …

Importance: Currently, there is no unified framework linking disease progression to
established viral levels, clinical tests, inflammatory markers, and investigational treatment …